Compare
Omeros Corp vs Prothena Corp Public Ltd Co vs ARS Pharmaceuticals, Inc. vs Liquidia Corp
| Latest fiscal year | Omeros Corp OMER | Prothena Corp Public Ltd Co PRTA | ARS Pharmaceuticals, Inc. SPRY | Liquidia Corp LQDA |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $9.68M | $84.28M | $158.32M |
| Revenue growth (YoY) | n/a | -92.8% | -5.5% | n/m |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/m | -212.9% | -32.5% |
| Net margin | n/a | n/m | -203.3% | -43.5% |
| Net income | -$3.35M | -$244.09M | -$171.30M | -$68.92M |
| EPS (Diluted) | -$0.05 | -$4.53 | -$1.74 | -$0.80 |
| Operating cash flow | -$116.09M | -$163.58M | -$170.87M | -$35.69M |
| Free cash flow | -$116.16M | n/a | -$171.21M | -$40.02M |
| Cash & equivalents | $9.66M | $307.53M | $41.32M | $190.68M |
| Total assets | $325.63M | $326.80M | $327.65M | $327.93M |
| Total liabilities | n/a | $46.33M | $213.39M | $283.19M |
| Shareholders' equity | -$121.23M | $280.47M | $114.26M | $44.75M |
| Return on year-end equity | n/a | -87.0% | -149.9% | -154.0% |
| Shares outstanding | 71.67M | 53.83M | 99.29M | 87.20M |
Revenue, most recent five fiscal years
| Fiscal year | Omeros Corp | Prothena Corp Public Ltd Co | ARS Pharmaceuticals, Inc. | Liquidia Corp |
|---|---|---|---|---|
| Latest | $73.81M Ended 2020-12-31 | $9.68M Ended 2025-12-31 | $84.28M Ended 2025-12-31 | $158.32M Ended 2025-12-31 |
| 1 year earlier | $111.81M Ended 2019-12-31 | $135.16M Ended 2024-12-31 | $89.15M Ended 2024-12-31 | $14.00M Ended 2024-12-31 |
| 2 years earlier | $29.87M Ended 2018-12-31 | $91.37M Ended 2023-12-31 | $30.0K Ended 2023-12-31 | $17.49M Ended 2023-12-31 |
| 3 years earlier | $64.83M Ended 2017-12-31 | $53.91M Ended 2022-12-31 | $1.32M Ended 2022-12-31 | $15.94M Ended 2022-12-31 |
| 4 years earlier | $41.62M Ended 2016-12-31 | $200.58M Ended 2021-12-31 | $5.51M Ended 2021-12-31 | $12.85M Ended 2021-12-31 |